An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis.

Uma Fogueri, Georgia Charkoftaki, Gavriel Roda, Stacey Tuey, Mustafa Ibrahim, Indushekhar Persaud, Michael F Wempe, Jared M Brown, Joshua M Thurman, Thomas J Anchordoquy, Melanie S Joy

Drug delivery and translational research 2022 Jun

filter terms:

Studies have suggested imatinib mesylate (ImM) as a potential treatment for systemic lupus erythematosus nephritis (SLEN). However, ImM has limited renal excretion. The goal of the current research was to develop an ImM containing nanoformulation, conduct studies to evaluate pharmacokinetics, and determine whether kidney deposition can be enhanced in a mouse model of SLEN. A fish oil-based ImM oil-in-water nanoemulsion was developed and characterized for particle size, zeta potential, pH, and stability. MRL/MpJ-Faslrp (model of SLEN) and MRL/MpJ (control) mice (12-13 weeks) received one dose of ImM as either a nanoemulsion or naked drug. Pharmacokinetics and kidney deposition studies were performed. Statistics were conducted with a student's T-test. The nanoemulsion characteristics included particle size range of 60-80 nm, zeta potential of -6.6 to -7.8 mV, polydispersity index < 0.3, 3-day stability at 4 °C, and limited ImM leakage from the nanoemulsion in serum. Pharmacokinetics of the nanoformulation showed changes to pharmacokinetic parameters suggesting reduced systemic exposures (with reduced potential for toxicities) to ImM. Kidney deposition of ImM was threefold higher after 4 h in the MRL/MpJ-Faslrp mice that received the nanoformulation vs. naked drug. The current study showed encouraging results for development of a stable and well-characterized nanoemulsion for optimizing kidney deposition of ImM. Future strategies will define dose-efficacy and dose-toxicity relationships and evaluate approaches to further enhance kidney delivery and optimize deposition to the mesangial location of the kidney. © 2021. Controlled Release Society.

Citation

Uma Fogueri, Georgia Charkoftaki, Gavriel Roda, Stacey Tuey, Mustafa Ibrahim, Indushekhar Persaud, Michael F Wempe, Jared M Brown, Joshua M Thurman, Thomas J Anchordoquy, Melanie S Joy. An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis. Drug delivery and translational research. 2022 Jun;12(6):1445-1454